期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

uPA/PAI系统和组织蛋白酶B与肝癌关系的研究进展

uPA/PAI system, cathepsin B and hepatocellular carcinoma
下载PDF
导出
摘要 尿激酶型纤溶酶原激活物/纤溶酶原激活剂抑制剂(urokinase-type plasminogen activator/plasminogen activator inhibitor,uPA/PAI)系统是一个蛋白水解酶激活剂/激活剂抑制剂系统,组织蛋白酶B(cathepsin B,Ctsb)是溶酶体内半胱氨酸蛋白水解酶.研究证明组织蛋白酶B能有效激活uPA,且他和uPA/PAI系统均与恶性肿瘤侵袭迁移的发生和恶性肿瘤血管形成密切相关.有研究发现,uPA/PAI系统和Ctsb在肝癌的发生发展也发挥了重要作用,故就此作一综述. Urokinase-type plasminogen activator and plas- minogen activator inhibitor （uPA/PAo are a pair of proteolytic enzyme activator/activator inhibi- tor. Cathepsin B is a lysosomal cysteine protease. It has been proved that cathepsin B can activate uPA. uPA/PAI and cathepsin B are closely re- lated to the invasion, migration and tumor angio- genesis of malignant neoplasms. The uPA/PAI system and cathepsin B play an important role in the occurrence and development of liver cancer.
作者 石清清 香基峤 陈兰 詹灵凌 吕小平
机构地区 广西医科大学第一附属医院消化内科 广西医科大学第一附属医院临床医学实验部
出处 《世界华人消化杂志》 CAS 北大核心 2014年第26期3941-3946,共6页 World Chinese Journal of Digestology
基金 广西自然科学基金资助项目 No.2012GXNSFAA053143 广西科学研究与技术开发计划基金资助项目 No.桂科攻1355005-3-2~~
关键词 uPA/PAI系统 组织蛋白酶B 肝细胞癌 uPA/PAI system Cathepsin B Hepato-cellular carcinoma
分类号 R735.7 [医药卫生—肿瘤]
  • 相关文献

参考文献51

  • 1Forner A, Llovet JM, Bruix J. Hepatocellular carci- noma. Lancet 2012; 379:1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0].
  • 2Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108 [PMID: 15761078].
  • 3EI-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273. el [PMID: 22537432 DOI: 10.1053/ j.gastro.2011.12.061].
  • 4Zhou Y, L X, Li S, Zhan L. Correlation between the overexpression of urokinase receptor isoform uPAR (DID2) and hepatic cell malignant transformation. Mol Med Rep 2014; 9:1689-1696 [PMID: 24604320 DOI: 10.3892/mmr.2014.2006].
  • 5Lee NP, Chen L, Lin MC, Tsang FH, Yeung C, Poon RT, Peng J, Leng X, Beretta L, Sun S, Day PJ, Luk JM. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocel- lular carcinoma. J Proteome Res 2009; 8:1293-1303 [PMID: 19161326 DOI: 10.1021/pr800637z].
  • 6Puxbaum V, Mach L. Proteinases and their inhibi- tors in liver cancer. World ] Hepatol 2009; 1:28-34 [PMID: 21160962 DOI: 10.4254/wjh.v1.il.28].
  • 7Guo M, Mathieu PA, Linebaugh B, Sloane BF, Reiners JJ. Phorbol ester activation of a proteolytic cascade capable of activating latent transform- ing growth factor-betaL a process initiated by the exocytosis of cathepsin B. J Biol Chem 2002; 277:14829-14837 [PMID: 11815600 DOh 10.1074/jbc. M108180200].
  • 8Gopinath S, Malla R, Alapati K, Gorantla B, Gujrati M, Dinh DH, Rao JS. Cathepsin B and uPAR regu- late self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Broil expression. Carci- nogenesis 2013; 34:550-559 [PMID: 23222817 DOI: 10.1093/carcin/bgs375].
  • 9Takada Y. Potential role of kringle-integrin interac- tion in plasmin and uPA actions (a hypothesis). J Biomed Biotechnol 2012; 2012:136302 [PMID: 23125522 DOI: 10.1155/2012/136302].
  • 10Tarui T, Akakura N, Majumdar M, Andronicos N, Takagi J, Mazar AP, Bdeir K, Kuo A, Yarovoi SV, Cines DB, Takada Y. Direct interaction of the krin- gle domain of urokinase-type plasminogen activa- tor (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost 2006; 95:524-534 [PMID: 16525582].

二级参考文献9

  • 1Choi Y K,Yoon B I,Kook Y H,et al, Overexpression of urokinasetype plasminogen activator in human goutric cancer cell line (AGS) induces timnnorigerricity in severe combined immunodeficient mice [ J]. Jpn J Cancer Res ,2002,3 ( 1 ) : 151-156.
  • 2Adachi Y, Chandrssekar N, Kin Y, et al. Suppression of glioms invssion and growth by adenovirus-medialed delivery of a bicistronic construct coutaining amisense uPAR and sense p16 gene sequences[ J ]. Oncogene ,2002,5 ( 1 ) :87-95.
  • 3Bhallacharya A,Lakka S S,Mohanarn S,et al. Regulation of the urokinase-type plasminogen activator receptor gene in defferent grades of human glioma cell lines [ J ]. Cancer Res 2001,7 ( 1 ) :267-276.
  • 4Blasi F, Carmeliet P. uPAR: a versatile signaling orchestrator[ J ]. Nat Rev Mol Cell Biol. 2002,21 (3) :932.
  • 5Xu L, Hui A Y, Albanis E, et al. Human hepatic stellate cell lines, Lx-1 and Lx-2: new tools for analysis of hepatic fibrosis [ J]. Gut, 2005,54 ( 1 ) : 142-151.
  • 6Legland H, Gentry J, Arthur M J, et al. The plasminogen-activating system in hepatic stellate cells [ J ]. Hepatology, 1996, 24 : 1172- 1178.
  • 7Carmelieti P L E, Schoonjans L, Kieckens B. Physiologyical consequences of loss of plasminogenactivator gene function in mice [ J ]. Nature, 1994,368:419-424.
  • 8Reuning U, Magdolen V, Wilhelm O, et al. Muhifunctional potential of the plasminogen activator system in tumor invasion and inetastasis ( review ) [ J ]. Int J Oncol, 1998,13 ( 5 ) : 893-906.
  • 9Andreasen P A, Egelund R, Petersen H H. The plasminogen activation system in tumor growth, invasion, and metastasis[ J]. Cell Mol Life Science,2000,57( 1 ) :25-40.

共引文献7

世界华人消化杂志
2014年 第26期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部